A multicenter non-randomized, uncontrolled single arm trial for evaluation of the efficacy and the safety of the treatment with favipiravir for patients with severe fever with thrombocytopenia syndrome

Koichiro Suemori1, Masayuki Saijo2*, Atsushi Yamanaka3, Daisuke Himeji3, Masafumi Kawamura4, Takashi Haku5, Michihito Hidaka6, Chinatsu Kamikokuryo7, Yasuyuki Kakihana7, Taichi Azuma1, Katsuto Takenaka1, Toru Takahashi1, Akitsu Furomotok9, Toshiyuki Ishimaru10, Masayuki Ishida11, Masahiko Kanekok12, Norimitsu Kadowakik13, Kenichi Ikeda14, Shigetoshi Sakabek15, Tomohiro Taniguchik16, Hiroki Ohge17, Takeshi Kurosuk17, Tomoki Yoshikawak2, Masayuki Shimojimak2, Masaki Yasukawak1

1 Department of Hematology, Clinical Immunology and Infectious Disease, Ehime University Graduate School of Medicine, Toon, Japan, 2 Department of Virology I, National Institute of Infectious Diseases, Shinjuku, Japan, 3 Department of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan, 4 Division of Internal Medicine, Kochi Prefectural Hata Kenmii Hospital, Sukumo, Kochi, Japan, 5 Department of Respiratory Medicine, Tokushima Prefectural Central Hospital, Tokushima, Japan, 6 Department of Hematology, National Hospital Organization Kumamoto Medical Center, Kumamoto, Japan, 7 Department of Emergency and Intensive Care Medicine, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Kagoshima, Japan, 8 Department of Hematology, Yamaguchi Grand Medical Center, Hofu, Japan, 9 Division of Infectious Diseases, Department of Internal Medicine, Nagaoka Rosai Hospital, Nagaoka, Japan, 10 Department of Infectious Diseases, The Japanese Red Cross Fukukoka Hospital, Hakata, Japan, 11 Department of Infectious Diseases, Chikamori Hospital, Kochi, Kochi, Japan, 12 Department of Internal Medicine, Uwajima City Hospital, Uwajima, Japan, 13 Division of Hematology, Kagawa University Hospital, Kida, Japan, 14 Department of Internal Medicine, Kagoshima City Hospital, Kagoshima, Japan, 15 Division of Infectious Diseases, Iae Red Cross Hospital, Ise, Japan, 16 Division of General Internal Medicine & Infectious Diseases, Hiroshima Prefectural Hospital, Hiroshima, Japan, 17 Department of Infectious Diseases, Hiroshima University Hospital, Hiroshima, Japan

* msaijo@nih.go.jp

Abstract

Severe fever with thrombocytopenia syndrome (SFTS) is a bunyavirus infection with high mortality. Favipiravir has shown effectiveness in preventing and treating SFTS virus (SFTSV) infection in animal models. A multicenter non-randomized, uncontrolled single arm trial was conducted to collect data on the safety and the effectiveness of favipiravir in treatment of SFTS patients. All participants received favipiravir orally (first-day loading dose of 1800 mg twice a day followed by 800 mg twice a day for 7–14 days in total). SFTSV RT-PCR and biochemistry tests were performed at designated time points. Outcomes were 28-day mortality, clinical improvement, viral load evolution, and adverse events (AEs). Twenty-six patients were enrolled, of whom 23 were analyzed. Four of these 23 patients died of multi-organ failure within one week (28-day mortality rate: 17.3%). Oral favipiravir was well tolerated in the surviving patients. AEs (abnormal hepatic function and insomnia) occurred...
in about 20% of the patients. Clinical symptoms improved in all patients who survived from a median of day 2 to day 10. SFTSV RNA levels in the patients who died were significantly higher than those in the survivors ($p = 0.0029$). No viral genomes were detectable in the surviving patients a median of 8 days after favipiravir administration. The 28-day mortality rate in this study was lower than those of the previous studies in Japan. The high frequency of hepatic dysfunction as an AE was observed. However, it was unclear whether this was merely a side effect of favipiravir, because liver disorders are commonly seen in SFTS patients. The results of this trial support the effectiveness of favipiravir for patients with SFTS.

Author summary

Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne virus infection caused by Dabie bandavirus (formerly SFTS virus, SFTSV), which belongs to the Bandavirus genus of the Phenuiviridae family. The case fatality rate of patients with SFTS is high ranging from 16.2% to 47%. SFTS is endemic to East and Southeast Asia. Favipiravir, an antiviral agent with an inhibitory activity on the RNA-dependent RNA polymerase, inhibited replication of SFTSV in vitro and in vivo. It was suggested that favipiravir treatment lowered the case fatality rate of patients with SFTS by approximately 10% in comparison with those reported so far through epidemiological survey in Japan. People living in the SFTS-endemic regions can not escape from the risk of being infected with SFTSV. Favipiravir might be an effective drug for treatment of patients with SFTS and reduces the mortality and morbidity of patients with SFTS.

Introduction

Severe fever with thrombocytopenia syndrome (SFTS) is a tick-borne virus infection caused by Dabie bandavirus (formerly SFTS virus, SFTSV), which belongs to the Bandavirus genus (formerly Phlebovirus genus) of the Phenuiviridae family (formerly Bunyaviridae family). SFTS has been identified in China, South Korea, and Japan since the early 2010s [1–4]. The virus name SFTSV is used in this article. SFTSV is maintained in nature between several species of tick and both wild and domestic animals [5]. Humans are usually infected with SFTSV through tick bites. Some patients with SFTS were infected with the virus through close contact with sick domestic animals such as cats infected with SFTSV [6]. SFTS patients were also reported in Vietnam and Taiwan [7–9].

The typical clinical manifestations are fever, fatigue, gastrointestinal symptoms, hemorrhagic tendency, and deterioration of consciousness. Leukocytopenia and thrombocytopenia appear in total blood cell counts, and levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), creatinine kinase (CK), and lactate dehydrogenase (LDH) are elevated in serum chemistry [1,4,10]. Patients with severe SFTS progress to multiple organ dysfunction, hemophagocytosis, and disseminated intravascular coagulation, and the majority of such cases prove fatal within 7–14 days after onset. Case fatality rates (CFRs) among SFTS patients were from 16.2%, 27–47%, and 27–31%, in China, South Korea, and Japan, respectively [11–14]. Older age and a high viral load are critical risk factors for SFTS mortality [13,15]. It is of note that the CFR in Japan was reported to be 31% [11] and 27% [12]. The aim of this study was to
evaluate an efficacy and a safety of antiviral therapy with favipiravir (6-fluoro-3-hydroxy-2-pyrazinecarboxamide) for patients with SFTS in Japan.

Ribavirin as an antiviral therapy and steroid pulse therapy and plasma exchange as supportive therapies have been applied to SFTS patients, although their efficacy remains limited [13,16–18]. Favipiravir, an RNA-dependent RNA polymerase inhibitor, which has been approved for influenza pandemic preparedness in Japan [19], showed efficacy for the prevention and treatment of SFTSV infection in animal models [20–22]. While interferon-α receptor knockout (IFNAR-KO) mice were infected with $1.0 \times 10^6$ 50% tissue culture infective dose (TCID₅₀) of SFTSV subcutaneously, all mice died within 5–7 days after infection, all the SFTSV-infected IFNAR−KO mice survived when the mice were administered with favipiravir within 3 days post infection [20,21]. The viremia level of the SFTSV-infected mice that were treated with favipiravir at the dose of 300 mg/kg/day became undetectable by highly sensitive SFTSV genome detection with quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) [15], even at 2 days after the initiation of favipiravir treatment [20]. Hamsters devoid of functional STAT2 (STAT2 knockout (KO) hamsters) are reported to be highly susceptible to as few as 10 plaque forming unit (PFU) of SFTSV. The hamsters succumb to death within 5 to 6 days after subcutaneous challenge. It was reported that SFTSV infection in STAT2 knockout (KO) hamsters infected with SFTSV were protected from lethal infection by the treatment with favipiravir [22].

Because SFTSV is circulating in nature, we can not escape from the risk of being infected with SFTSV. Development of therapeutics is required for patients with SFTS [23]. In the present study, a prospective, open-label, single arm, multi-center study was conducted to evaluate the efficacy and the safety of favipiravir in the treatment of SFTS patients in Japan.

**Patients and methods**

**Ethics statement**

The study protocol, informed consent form, and all other required documents were reviewed and approved by an Independent Ethics Committee for each study site before initiation of the study at that site. The identification number for approval issued was #684 from the Research and Ethics Committee of the National Institute of Infectious Diseases (NIID). The identification numbers for approval issued from the institutional ethical committee of each hospital are #1603038 and #1708017 (Ehime University Graduate School of Medicine), #16–09 (Miyazaki Prefectural Miyazaki Hospital), #H28–24 (Kochi Prefectural Hata Kenmin Hospital), #16–1 (Tokushima Prefectural Central Hospital), #674 (National Hospital Organization Kumamoto Medical Center), #2017–017 (Yamaguchi Grand Medical Center), #29010 (Nagasaki Rosai Hospital), #374 (The Japanese Red Cross Fukuoka Hospital), #212 (Chikamori Hospital), #167–101 (Uwajima City Hospital), #H28–037 and #H29–136 (Kagawa University Hospital), #2017–36 (Kagoshima City Hospital), #29–53 (Ise Red Cross Hospital), #2016–001 and #H28–21 (Hiroshima Prefectural Hospital), #170200 (Kagoshima University Graduate School of Medical and Dental Sciences), and #C–93 and #C–210–2 (Hiroshima University Hospital). This study was conducted in accordance with Japanese Ethical Guidelines for Medical and Health Research Involving Human Subjects (December 2014). These guidelines are consistent with the World Medical Assembly Declaration of Helsinki. Written informed consent was obtained from each subject or advocate for the subject (spouse or lineal relatives) before any study-specific procedures were performed.

**Study design**

The primary endpoint was overall survival (OS), which was defined as the mortality rate during the 28-day period after the introduction of favipiravir, in the enrolled cohort. The
secondary endpoints were the time until SFTSV became undetectable in peripheral blood as measured by virus isolation assay [4], changes in the SFTSV load determined by quantitative real-time reverse transcription polymerase chain reaction (qRT-PCR) [15], and the time until alleviation of clinical symptoms and normalisation of laboratory parameters. This study was conducted during two periods, April to December 2016 and September 2017 to July 2018, mainly in western Japan. Microbiological tests including blood, urine, and throat cultures were performed routinely depend on the patients’ conditions by the attending physicians. However, it was of note that the microbiological tests except for SFTS-associated tests were not included in the study protocol.

Participants

Participants were patients diagnosed as or strongly suspected of having SFTS and who satisfied both the inclusion and exclusion criteria.

Inclusion criteria were as follows: 1) patients aged 20 years or older, 2) patients diagnosed as having SFTS with SFTSV genome positive by both the conventional RT-PCR and the qRT-PCR [15] before favipiravir-treatment initiation, 3) patients strongly suspected of having SFTS on the basis of findings such as a tick bite, temperature ≥38°C, WBC count <4,000/μL, platelet count <100,000/μL, gastrointestinal tract symptoms (nausea, vomiting, abdominal pain, diarrhea, melena), and occult hematuria, and 4) patients who understood the requirements of the study and provided written informed consent prior to undergoing any study-related procedures.

Exclusion criteria were as follows: 1) patients whose clinical symptoms had already improved or whose SFTSV load in peripheral blood had already been in the decreasing phase, 2) patients in whom more than seven days had passed from onset of symptoms, 3) patients who had been treated for Grade C-equivalent liver impairment based on the Child-Pugh classification [24], 4) patients who were pregnant or had a positive pregnancy test prior to initial dosing, 5) patients who had difficulty in adhering to very effective measures of contraception with their partners during favipiravir treatment and for seven days following the last dose of favipiravir, 6) patients with hereditary xanthinuria, a history of hypouricemia (urea acid <1 mg/dL), or xanthine calculi in the urinary tract, 7) patients who had a history of hypersensitivity to favipiravir, 8) patients who were deemed ineligible for any reason by the principal investigator or subinvestigator, and 9) patients, who were treated with ribavirin or drugs and medical equipment under development.

Rank classification of clinical symptoms and laboratory findings

The severity of clinical symptoms and laboratory findings were classified in accordance with a pre-specified rank for making it available to assess the clinical course of the SFTS patients treated with favipiravir in terms of severity and outcome (S1 Table). In brief, the classifications were as follows, Rank 1, normal level; Rank 2, mild level; Rank 3, moderate level; and Rank 4, severe level.

Virological test for SFTSV detection and isolation

SFTSV infection was confirmed using the conventional RT-PCR at the local public health institutions and/or the NIID, as described previously [15]. Quantitative real-time RT-PCR was also performed on peripheral blood collected throughout the study (every 3 days from the day of fever onset until day 19 of disease) at the NIID. Virus culture was performed to evaluate the day on which infectious SFTSV became undetectable. Peripheral blood samples were collected throughout the study (every 3 days from the day of fever onset until day 10 of disease) for virus culture testing.
Usage, dose, and administration period of favipiravir

Patients were administered favipiravir orally at a loading dose of 1,800 mg twice a day on the first day followed by 800 mg twice a day for 7–14 days in total. If the patients could not take favipiravir tablets orally, the patients were administered the tablet in a simple suspension form through a gastric tube.

Safety assessments

Adverse events (AEs) were evaluated by attending physicians until 28 days after the start of favipiravir administration, regardless of whether they had any causal relationship with the favipiravir. The severity of AEs was classified into the following three grades in accordance with a notice from the Ministry of Health, Labour and Welfare of Japan (MHLW) [25]: Grade 1: AE mild, allowing the study to be continued and not interfering with daily life; Grade 2: AE moderate, causing the study to disturb daily life but not affecting function; Grade 3: AE moderate, causing the study to disturb daily life and possibly leading to permanent malfunction requiring medical treatment; or severe AE: fatal, life-threatening, extension of hospitalisation, permanent or marked disability and malfunction, occurrence of birth defects and medically important abnormality. Adverse reactions (ARs) were evaluated by attending physicians based on the pharmaceutical document providing information on the side effects of favipiravir.

Data management

Demographic patient data were recorded by the principal investigator or subinvestigator on a pre-designed case report form. The anonymized demographic data included subject ID, date of provision of informed consent, date of birth, sex, race and nationality, weight, height, medical history, allergies, date of fever onset, diagnosis, and pregnancy status. These data were collected before favipiravir-treatment initiation. The demographic data together with data from laboratory sample report forms containing sample ID, sample type, collection date, date of symptom onset, and SFTSV RT-PCR results were entered in a database (Excel, Microsoft) at the Center for Clinical Research Data and Biostatistics, Ehime University Hospital, Toon, Ehime, Japan. Data recorded were checked for consistency with the source data by the research staff. Data were managed according to standard operating procedures established in advance.

Statistical analysis

All categorical variables are presented with absolute frequency counts and percentages. Verification of all analyses and summaries were conducted using SAS software Version 9.4 (SAS Institute Inc., Cary, NC). The characteristics of patients who survived were compared with those of patients who died using the Student t-test or Mann-Whitney U test for continuous variables and Fisher’s exact test for categorical variables. Survival time for SFTS patients was plotted using the Kaplan-Meier method. The difference in the survival rates between patients with higher viremia and those with relatively lower viremia was statistically evaluated with Log-rank test. Number of events, number censored, median time to event, and its 95% confidence interval are presented in the analysis table. All statistical testing was two-sided at a type-I error rate of 0.05.

Monitoring of favipiravir blood levels

Blood samples were taken post-dose (1 to 2 hours after dosing in the morning) on day 1 and pre-dose (just prior to dosing in the morning) and post-dose (1 to 2 hours after dosing in the morning) on days 4 and 7 or 10. Model-based pharmacokinetic analysis was conducted to
estimate the time course of favipiravir blood levels in the subjects mainly using Phoenix WinNonlin version 6.3 (Certara LP, Princeton, NJ). The blood samples for monitoring of favipiravir blood levels were taken only from the patients, who participated in this study during the first period of April—December 2016.

Results

Characteristics and outcome of the participants

Twenty-six patients aged between 42 and 91 years were enrolled (Fig 1).

Three patients who were suspected of having SFTS were initially included but were then ultimately excluded because their blood samples were negative for SFTSV by conventional RT-PCR. Therefore, 23 patients were enrolled for further analyses. Nineteen patients (Non-fatal group) completed the study medication course, whereas 4 patients, who died (Fatal group), could not. The four who died did so of multiple organ failure within 6 days, resulting in an overall survival (OS) rate of 82.6% (Fig 2A).

The basic characteristics of the patients are summarised (Table 1).

The median age of the patients was 71 years, and 14 of them were men. There were no significant differences between the Fatal and Non-fatal groups in terms of age, weight, body mass index, and time from disease onset until favipiravir initiation. Underlying diseases were reported in 19 of the study patients (82.6%): hypertension in twelve, hyperlipidemia in five, diabetes mellitus in four, and cancer in one. There was a statistical difference in having hypertension between the two groups.

Clinical characteristics of the patients on admission

The signs and symptoms evident on admission did not significantly differ between the Fatal and Non-fatal groups (S2 Table). Laboratory findings on admission are summarised in

![Patient flow diagram](https://doi.org/10.1371/journal.pntd.0009103.g001)

Enrolled and received favipiravir (n=26)

- Efficacy analysis population (n=23)
  - Excluded due to negative RT-PCR (n=3)
  - Completed study medication (n=19)
    - Did not complete study medication due to fatal outcome (n=4)

- PK analysis population (n=7)
  - Excluded (n=19)
    - PK samples were not taken (n=13)
    - Sufficient PK data were not available (n=3)
    - RT-PCR negative (n=3)
Table 2. The viral genome load was the only factor that differed significantly between the Fatal and Non-fatal groups. The viral genome loads in the Fatal group patients was $3.16 \times 10^6$ copies/mL and was significantly higher than that of $5.01 \times 10^4$ copies/mL in the Non-fatal group ($p = 0.0029$). The rank classification of diarrhea and the serum LDH level on admission differed significantly between the two groups ($p = 0.03$ and $p = 0.02$, respectively) among the symptoms and the laboratory parameters evaluated (Table 2).
The rank classification of clinical symptoms and laboratory findings on admission are summarised (Table 3).

The time to resolution (rank 0) of clinical symptoms and laboratory findings in the Non-fatal group is shown (Table 4).

Table 1. Basic characteristics of the 23 SFTS patients who received favipiravir.

| Categories          | Subcategories | Overall (n = 23) | Groups                     | p-Value   |
|---------------------|---------------|-----------------|----------------------------|-----------|
|                     |               |                 | Fatal (n = 4)               | Non-fatal (n = 19) |
| Gender              | Male          | 14 (60.9%)      | 1 (25%)                    | 13 (68.4%)| 0.2601† |
|                     | Female        | 9 (39.1%)       | 3 (75%)                    | 6 (31.6%) |           |
| Age (years)         | Median (IQR)  | 71.0 (65, 81)   | 73.5 (63.5)                | 71.0 (65, 81) | 0.9031† |
|                     | < 60          | 2 (8.7%)        | 0 (0%)                     | 2 (10.5%) | 0.7123* |
|                     | 60–79         | 14 (60.9%)      | 2 (50%)                    | 12 (63.2%)|           |
|                     | ≥ 80          | 7 (30.4%)       | 2 (50%)                    | 5 (26.3%) |           |
| Weight (kg)         | Median (IQR)  | 57.3 (50.0, 69.4) | 47.5 (45.7, 58.7)       | 59.1 (50.4, 71.0) | 0.1230† |
|                     | BMI (kg/m²)   | 22.2 (19.9, 25.1) | 21.4 (20.4, 23.4)        | 23.1 (19.7, 26.0) | 0.5429† |
| Time from onset to favipiravir initiation (days) | Median (IQR) | 4 (3.5) | 4.5 (3.5) | 4.0 (3.5) | 0.7730† |

Underlying disease

|                  |                | Overall (n = 23) | Groups                     | p-Value   |
|------------------|----------------|-----------------|----------------------------|-----------|
|                  |                |                 | Fatal (n = 4)               | Non-fatal (n = 19) |
| Diabetes mellitus| Diabetic       | 4 (17.4%)       | 0 (0%)                     | 4 (21.1%) | 1.00*    |
|                  | Diabetes       | 10 (43.5%)      | 2 (50%)                    | 8 (42.1%) |           |
|                  | Nondiabetic    | 9 (39.1%)       | 2 (50%)                    | 7 (36.8%) |           |
| Cancer           |                | 1 (4.4%)        | 0 (0%)                     | 1 (5.3%)  | 1.00*    |
| Hypertension     |                | 12 (52.2%)      | 0 (0%)                     | 12 (63.2%)| 0.0373*  |
| Hyperlipidaemia  |                | 5 (21.7%)       | 0 (0%)                     | 5 (26.3%) | 0.5392*  |

* Fisher’s exact test.
† Mann-Whitney U test.
Ω measured before initiation of favipiravir treatment.

n = number, IQR = interquartile range, BMI = body mass index.

https://doi.org/10.1371/journal.pntd.0009103.t001

Table 2. Laboratory findings on admission.

| Categories          | Normal range* | Overall [Mean (SD)] | Groups                     | p-Value† |
|---------------------|---------------|---------------------|----------------------------|-----------|
|                     |               |                     | Fatal (n = 4)               | Non-fatal (n = 19) |
| WBC (/mm³)          | 3,300–8,600   | 2,737 (2,527)       | 1,337 (457)                | 3,032 (2691) | 0.2312 |
| Hb (g/dL)           | M: 13.7–16.8  | 14.2 (2.2)          | 14.2 (1.4)                 | 14.2 (2.4)  | 0.9786 |
|                     | F: 11.6–14.8  |                     |                            |            |        |
| Pt (×10⁷/mm³)       | 15.8–34.8     | 5.2 (1.4)           | 5.2 (1.2)                  | 5.2 (1.5)  | 0.9909 |
| Albumin (g/dL)      | 4.1–5.1       | 3.1 (0.6)           | 3.2 (1.0)                  | 3.1 (0.5)  | 0.6138 |
| AST (U/L)           | 13–30         | 278 (193)           | 367 (161)                  | 259 (197)  | 0.3189 |
| ALT (U/L)           | M: 10–42      | 110 (80.9)          | 154 (97.7)                 | 101 (76.7) | 0.2422 |
|                     | F: 7–23       |                     |                            |            |        |
| LDH (U/L)           | 124–222       | 890 (431)           | 926 (123)                  | 882 (473)  | 0.8541 |
| CK (U/L)            | M: 59–248     | 1,897 (2,430)       | 1,105 (1,001)              | 2,064 (2,623) | 0.4859 |
|                     | F: 41–153     |                     |                            |            |        |
| Cr (mg/dL)          | M: 0.65–0.07  | 1.07 (0.76)         | 0.79 (0.19)                | 1.13 (0.82) | 0.4254 |
|                     | F: 0.46–0.79  |                     |                            |            |        |
| BUN (mg/dL)         | 8–20          | 22.4 (11.2)         | 17.7 (5.9)                 | 23.3 (11.9) | 0.3768 |
| CRP (mg/dL)         | 0.00–0.14     | 0.9 (1.1)           | 1.0 (1.4)                  | 0.9 (1.0)  | 0.9435 |
| Ferritin (ng/mL)    | M: 18.6–261   | 8,156 (112 340)     | 16,367 (23 629)           | 6,428 (6 574) | 0.1094 |
|                     | F: 4.0–64.2   |                     |                            |            |        |
| Viral genome load (log₁₀ copies/mL) | 5.0 (1.2) | 6.5 (1.5) | 4.7 (0.9) | 0.0029 |

* Japanese Committee For Clinical Laboratory Standards, JCCLS
† Student t-test.

https://doi.org/10.1371/journal.pntd.0009103.t002
Table 3. Rank classification of clinical symptoms and laboratory findings on admission.

| Clinical symptoms and laboratory findings | Number of patients evaluated | Rank | Overall | Groups | p-Value* |
|------------------------------------------|-----------------------------|------|---------|--------|----------|
|                                          |                             |      |         | Fatal  | Non-fatal|
| Body temperature                         | 23                          | 1    | 8 (34.8%) | 1/4 (25.0%) | 7/19 (36.8%) | 0.66 |
|                                          |                             | 2    | 8 (34.8%) | 1/4 (25.0%) | 7/19 (36.8%) |
|                                          |                             | 3    | 5 (21.7%) | 1/4 (25.0%) | 4/19 (21.1%) |
|                                          |                             | 4    | 2 (8.7%)  | 1/4 (25.0%) | 1/19 (5.3%)  |
| Headache                                 | 19                          | 1    | 13 (68.4%) | 1/3 (33.3%) | 12/16 (75.0%) | 0.09 |
|                                          |                             | 2    | 5 (26.3%)  | 1/3 (33.3%) | 4/16 (25.0%)  |
|                                          |                             | 3    | 1 (5.3%)   | 1/3 (33.3%) | 0/16 (0%)   |
|                                          |                             | 4    | 0 (0%)     | 0/3 (0%)   | 0/16 (0%)   |
| Body aches and pains                     | 18                          | 1    | 12 (66.7%) | 2/3 (66.7%) | 10/15 (66.7%) | 1.00 |
|                                          |                             | 2    | 2 (11.1%)  | 0/3 (0%)   | 2/15 (13.3%) |
|                                          |                             | 3    | 4 (22.2%)  | 1/3 (33.3%) | 3/15 (20.0%) |
|                                          |                             | 4    | 0 (0%)     | 0/3 (0%)   | 0/15 (0%)   |
| Vomiting                                 | 21                          | 1    | 17 (81.0%) | 4/4 (100%)  | 13/17 (76.5%) | 0.55 |
|                                          |                             | 2    | 4 (19.0%)  | 0/4 (0%)   | 4/17 (23.5%) |
|                                          |                             | 3    | 0 (0%)     | 0/4 (0%)   | 0/17 (0%)   |
|                                          |                             | 4    | 0 (0%)     | 0/4 (0%)   | 0/17 (0%)   |
| Abdominal pain                           | 18                          | 1    | 12 (66.7%) | 1/3 (33.3%) | 11/15 (73.3%) | 0.10 |
|                                          |                             | 2    | 5 (27.8%)  | 1/3 (33.3%) | 4/15 (26.7%) |
|                                          |                             | 3    | 1 (5.6%)   | 1/3 (33.3%) | 0/15 (0%)   |
|                                          |                             | 4    | 0 (0%)     | 0/3 (0%)   | 0/15 (0%)   |
| Diarrhea                                 | 20                          | 1    | 10 (50.0%) | 0/3 (0%)   | 10/17 (58.8%) | 0.03 |
|                                          |                             | 2    | 7 (35.0%)  | 1/3 (33.3%) | 6/17 (35.3%) |
|                                          |                             | 3    | 2 (10.0%)  | 1/3 (33.3%) | 1/17 (5.9%)  |
|                                          |                             | 4    | 1 (5.0%)   | 1/3 (33.3%) | 0/17 (0%)   |
| Dyspnea                                  | 18                          | 1    | 13 (72.2%) | 2/2 (100%)  | 11/16 (68.8%) | 1.00 |
|                                          |                             | 2    | 4 (22.2%)  | 0/2 (0%)   | 4/16 (25.0%) |
|                                          |                             | 3    | 1 (5.6%)   | 0/2 (0%)   | 1/16 (6.3%)  |
|                                          |                             | 4    | 0 (0%)     | 0/2 (0%)   | 0/16 (0%)   |
| Hemorrhage                               | 22                          | 1    | 18 (81.8%) | 4/4 (100%)  | 14/18 (77.8%) | 1.00 |
|                                          |                             | 2    | 1 (4.5%)   | 0/4 (0%)   | 1/18 (5.6%)  |
|                                          |                             | 3    | 1 (4.5%)   | 0/4 (0%)   | 1/18 (5.6%)  |
|                                          |                             | 4    | 2 (9.1%)   | 0/4 (0%)   | 2/18 (11.1%) |
| Disorientation                           | 21                          | 1    | 9 (42.9%)  | 1/4 (25.0%) | 8/17 (47.1%)  | 0.53 |
|                                          |                             | 2    | 9 (42.9%)  | 2/4 (50.0%) | 7/17 (41.2%)  |
|                                          |                             | 3    | 2 (9.5%)   | 1/4 (25.0%) | 1/17 (5.9%)  |
|                                          |                             | 4    | 1 (4.8%)   | 0/4 (0%)   | 1/17 (5.9%)  |
| WBC                                      | 23                          | 1    | 2 (8.7%)   | 0/4 (0%)   | 2/19 (10.5%)  | 0.21 |
|                                          |                             | 2    | 9 (39.1%)  | 0/4 (0%)   | 9/19 (47.4%)  |
|                                          |                             | 3    | 10 (43.5%) | 3/4 (75.0%) | 7/19 (36.8%)  |
|                                          |                             | 4    | 2 (8.7%)   | 1/4 (25.0%) | 1/19 (5.3%)  |
| Pht                                      | 23                          | 1    | 0 (0%)     | 0/4 (0%)   | 0/19 (0%)   | 0.66 |
|                                          |                             | 2    | 1 (4.3%)   | 0/4 (0%)   | 1/19 (5.3%)  |
|                                          |                             | 3    | 12 (52.2%) | 3/4 (75.0%) | 9/19 (47.4%)  |
|                                          |                             | 4    | 10 (43.5%) | 1/4 (25.0%) | 9/19 (47.4%)  |

(Continued)
Table 3. (Continued)

| Clinical symptoms and laboratory findings | Number of patients evaluated | Rank | Overall | Groups          | p-Value* |
|-------------------------------------------|-----------------------------|------|---------|-----------------|----------|
|                                           |                             | 1    | 0 (0%)  | 0 /4 (0%)       | 0/19 (0%)| 0.69    |
|                                           |                             | 2    | 4 (17.4%) | 0/4 (0%)       | 4/19 (21.1%) |        |
|                                           |                             | 3    | 2 (8.7%)  | 0/4 (0%)       | 2/19 (10.5%) |        |
|                                           |                             | 4    | 17 (73.9%) | 4/4 (100%)     | 13/19 (68.4%) |        |
| AST                                       | 23                          | 1    | 4 (17.4%)  | 0/4 (0%)       | 4/19 (21.1%) | 0.09    |
|                                           |                             | 2    | 8 (34.8%)  | 0/4 (0%)       | 8/19 (42.1%) |        |
|                                           |                             | 3    | 5 (21.7%)  | 2/4 (50.0%)    | 3/19 (15.8%) |        |
|                                           |                             | 4    | 6 (26.1%)  | 2/4 (50.0%)    | 4/19 (21.1%) |        |
| ALT                                       | 23                          | 1    | 0 (0%)    | 0 /4 (0%)      | 0/19 (0%)  | 0.02    |
|                                           |                             | 2    | 8 (34.8%)  | 0/4 (0%)       | 8/19 (42.1%) |        |
|                                           |                             | 3    | 9 (39.1%)  | 4/4 (100%)     | 5/19 (26.3%) |        |
|                                           |                             | 4    | 6 (26.1%)  | 0/4 (0%)       | 6/19 (31.6%) |        |
| LDH                                       | 23                          | 1    | 0 (0%)    | 0 /4 (0%)      | 0/19 (0%)  | 1.00    |
|                                           |                             | 2    | 6 (26.1%)  | 1/4 (25.0%)    | 2/19 (10.5%) |        |
|                                           |                             | 3    | 9 (39.1%)  | 4/4 (100%)     | 5/19 (26.3%) |        |
|                                           |                             | 4    | 11 (47.8%) | 2/4 (50.0%)    | 9/19 (47.4%) |        |
| CK                                        | 23                          | 1    | 3 (13.0%)  | 0/4 (0%)       | 3/19 (15.8%) |        |
|                                           |                             | 2    | 3 (13.0%)  | 1/4 (25.0%)    | 2/19 (10.5%) |        |
|                                           |                             | 3    | 6 (26.1%)  | 1/4 (25.0%)    | 5/19 (26.3%) |        |
|                                           |                             | 4    | 11 (47.8%) | 2/4 (50.0%)    | 9/19 (47.4%) |        |
| Viral load                                | 23                          | 1    | 0 (0%)    | 0 /4 (0%)      | 0/19 (0%)  | 0.053   |
|                                           |                             | 2    | 5 (23%)   | 0/4 (0%)       | 5/19 (26.3%) |        |
|                                           |                             | 3    | 13 (56.5%) | 1/4 (25.0%)    | 12/19 (63.2%) |        |
|                                           |                             | 4    | 5 (21.7%)  | 3/4 (75.0%)    | 2/19 (10.5%) |        |

* Fisher’s exact test.

WBC = white blood cell count, Plt = platelet count, AST = aspartate transaminase, ALT = alanine transaminase, LDH = lactate dehydrogenase, CK = creatine kinase.

https://doi.org/10.1371/journal.pntd.0009103.t003

Table 4. Time until resolution of clinical symptoms and normalization of laboratory parameters in the Non-fatal group.

| Clinical symptoms and laboratory findings | Number evaluated | Median days | 95% CI       |
|------------------------------------------|------------------|-------------|--------------|
| Body temperature                         | 19               | 4.0         | 2.0, 8.0     |
| Headache                                 | 18               | 4.0         | 2.0, 8.0     |
| Body aches and muscle pains              | 18               | 8.0         | 2.0, 13.0    |
| Vomiting                                 | 19               | 2.0         | 2.0, 8.0     |
| Abdominal pain                           | 18               | 2.5         | 2.0, 13.0    |
| Diarrhea                                 | 19               | 5.0         | 2.0, 12.0    |
| Dyspnea                                  | 17               | 10.0        | 4.0, 21.0    |
| Hemorrhage                               | 19               | 10.0        | 5.0, 22.0    |
| Disorientation                           | 19               | 11.0        | 3.0, 14.0    |
| Plt                                      | 19               | 10.0        | 8.0, 14.0    |
| WBC                                      | 19               | 11.0        | 7.0, 28.0    |
| AST                                      | 19               | 23.0        | 14.0         |
| ALT                                      | 19               | 21.0        | 20.0, 26.0   |
| LDH                                      | 19               | 28.0        | 22.0         |
| CK                                       | 19               | 10.5        | 7.0, 14.0    |
| Viral load                               | 19               | 7.0         | 6.0, 9.0     |

CI = confidence interval, Plt = platelet count, WBC = white blood cell count, AST = aspartate transaminase, ALT = alanine transaminase, LDH = lactate dehydrogenase, CK = creatine kinase.

https://doi.org/10.1371/journal.pntd.0009103.t004
Among the clinical symptoms, vomiting and abdominal pain improved early at a median of 2 and 2.5 days, respectively. However, improvement of dyspnea, hemorrhage, and disorientation occurred later, at a median of 10, 10, and 11 days, respectively. Among laboratory parameters, the WBC and platelet counts and CK level improved at a median of 10, 11, and 10.5 days, respectively. The improvements in AST, ALT, and LDH levels occurred much later at a median of 23, 21, and 28 days, respectively. SFTSV genome became negative in all the patients in the Non-fatal group by 16 days with a median of 13 days.

Each of the combination therapies offered to the patients participated was not initiated in relation with favipiravir treatment, but was initiated based on each patient’s conditions by the attending physicians. There was no significant difference in the combination therapies performed for each patient based on the attending physicians’ decision between the Fatal and Non-fatal groups in terms of combination therapy, except for the incidence of mechanical ventilation (Table 5). Corticosteroid therapy including steroid pulse therapy was performed for 11 of 23 patients targeting a pathophysiology of hemophagocytic syndrome-associated cytokine storm, which is one of the main factors for poor prognosis of SFTS patients [4,26–29], although the steroid therapy had not been confirmed to be effective for SFTS patients. In the present study, there was no significant relationship between patients who received corticosteroid therapy and those who received mechanical ventilation respiratory support therapy.

Viremia level and virus isolation in SFTS patients treated with favipiravir

The viral load decreased day by day in the patients overall (Fig 3A). However, the course of the SFTSV load in the Fatal group was apparently different from that in the Non-fatal group. The sequential viral load in Fatal group patients is shown (Fig 3B). The rates of positive virus isolation decreased as the disease course progressed (Fig 3C). Viral clearances evaluated with virus isolation and qRT-PCR in the Non-fatal group were obtained after a median of 8 days and 13 days, respectively (Table 4).

Table 5. Combination therapy performed for enrolled patients with SFTS.

| Treatment categories | Overall (n = 23) | Groups | p-Value* |
|----------------------|-----------------|--------|----------|
|                      | Fatal (n = 4)    | Non-fatal (n = 19) |          |
| Corticosteroids      | 11 (48%)        | 3 (75%) | 8 (42%)  | 0.32     |
| Steroid pulse therapy| 8 (35%)         | 2 (50%) | 6 (32%)  | 0.59     |
| Antimicrobial agents  |                 |         |          |          |
| Quinolone            | 10 (43%)        | 1 (25%) | 9 (47%)  | 0.6      |
| Tetracycline         | 5 (22%)         | 1 (25%) | 4 (21%)  | 1.00     |
| Glycopeptide         | 2 (9%)          | 0 (0%)  | 2 (11%)  | 1.00     |
| Other                | 1 (4%)          | 0 (0%)  | 1 (5%)   | 1.00     |
| Candin               | 6 (26%)         | 0 (0%)  | 6 (32%)  | 0.54     |
| Blood products transfused |            |         |          |          |
| Platelets            | 8 (35%)         | 3 (75%) | 5 (26%)  | 0.10     |
| Red blood cells      | 2 (9%)          | 1 (25%) | 1 (5%)   | 0.32     |
| Fresh frozen plasma  | 2 (9%)          | 0 (0%)  | 2 (11%)  | 1.00     |
| Immunoglobulin       | 4 (17%)         | 1 (25%) | 3 (16%)  | 1.00     |
| Thrombomodulin       | 3 (13%)         | 1 (25%) | 2 (11%)  | 0.45     |
| Blood purification therapy |        |         |          |          |
| Mechanical ventilation| 6 (26%)         | 3 (75%) | 3 (16%)  | 0.04     |

* Fisher’s exact test.

https://doi.org/10.1371/journal.pntd.0009103.t005
Adverse events and reactions

AEs and ARs as judged by the attending physicians are summarised (Table 6). The frequency of AEs and ARs was 87% and 56.5%, respectively. Serious AEs occurred in four patients, and the serious ARs were death and convulsion. AEs leading to treatment discontinuation occurred in the four patients who died. Hepatic dysfunction and insomnia were the AEs that occurred in 20% or more of the patients.

Viremia level and survival probability

Survival probability in relation to viral load at the start of favipiravir administration was statistically significant with a virus genome load of $1 \times 10^5$ copies/mL ($p = 0.01$) (Fig 2B). The SFTSV survival rate in terms of the isolation test for SFTSV decreased as the course of
favipiravir treatment progressed. The CFRs in SFTS patients with SFTS $\geq 1 \times 10^5$ copies/mL of SFTSV genome viremia and those with SFTS $< 1 \times 10^5$ copies/mL of SFTSV genome viremia in the present study was 40% (4/10) and 0% (0/13), respectively, with a significant difference (P-value of 0.013, Log-rank test). The patients in the Fatal group died within 6 days from the favipiravir treatment initiation (Fig 2B).

**Pharmacokinetics of favipiravir in patients with SFTS**

Pharmacokinetic analysis was performed using samples from 7 patients (Fig 4). The trough and peak mean concentrations of blood favipiravir were predicted to be about 40 μg/mL and 60 μg/mL, respectively. The blood samples were collected for favipiravir blood concentration

---

Table 6. Summary of adverse events and adverse reactions.

| Categories                                                      | Efficacy population (n = 23) |
|-----------------------------------------------------------------|------------------------------|
| n                  | %  | 95% CI                  |
| Any adverse event (AE)                                        | 20  | 87.0  | 66.4, 97.2 |
| Grade 1                                                       | 14  | 60.9  | 38.5, 80.3 |
| Grade 2                                                       | 7   | 30.4  | 13.2, 52.9 |
| Grade 3                                                       | 7   | 30.4  | 13.2, 52.9 |
| Serious AE                                                    | 4   | 17.4  | 5.0, 38.8  |
| Any adverse reaction (AR)                                     | 13  | 56.5  | 34.5, 76.8 |
| Grade 1                                                       | 8   | 34.8  | 16.4, 57.3 |
| Grade 2                                                       | 6   | 26.1  | 10.2, 48.4 |
| Grade 3                                                       | 2   | 8.7   | 1.1, 28.0  |
| Serious AR$^*$                                                 | 1   | 4.3   | 0.1, 21.9  |
| AE leading to treatment discontinuation (HLGT/PT)              | 4   | 17.4  | 5.0, 38.8  |
| Fatal outcomes                                                | 2   | 8.7   | 1.1, 28.0  |
| Death                                                         | 2   | 8.7   | 1.1, 28.0  |
| General system disorders NEC                                   | 1   | 4.3   | 0.1, 21.9  |
| Condition aggravated                                          | 1   | 4.3   | 0.1, 21.9  |
| Hepatic and hepatobiliary disorders                           | 2   | 8.7   | 1.1, 28.0  |
| Hepatic function abnormal                                     | 2   | 8.7   | 1.1, 28.0  |
| Renal disorders (excl. nephropathies)                         | 1   | 4.3   | 0.1, 21.9  |
| Acute kidney injury                                           | 1   | 4.3   | 0.1, 21.9  |
| AE occurring in 20% or more (HLGT/PT)                         | 6   | 26.1  | 10.2, 48.4 |
| Epidermal and dermal conditions                               | 2   | 8.7   | 1.1, 28.0  |
| Generalised erythema                                          | 1   | 4.3   | 0.1, 21.9  |
| Pruritus                                                       | 1   | 4.3   | 0.1, 21.9  |
| Rash                                                          | 3   | 13    | 2.8, 33.6  |
| Hepatic and hepatobiliary disorders                           | 8   | 34.8  | 16.4, 57.3 |
| Hepatic function abnormal                                     | 5   | 21.7  | 7.5, 43.7  |
| Hyperbilirubinemia                                            | 2   | 8.7   | 1.1, 28.0  |
| Liver disorder                                                | 1   | 4.3   | 0.1, 21.9  |
| Sleep disorders and disturbances                              | 5   | 21.7  | 7.5, 43.7  |
| Insomnia                                                      | 5   | 21.7  | 7.5, 43.7  |

$^*$ Preferred term, Seizure

** System Organ Class, Hepatobiliary disorders

n = number, CI = confidence interval, HLGT = High Level Group Term, PT = Preferred Term, NEC = Not Elsewhere Classified.

https://doi.org/10.1371/journal.pntd.0009103.t006
measurement only from 12 patients, who participated in the first study period. The blood collection for this purpose was not completed in 2 patients who died and 3 patients because of the patients’ conditions and/or technical issues.

**Discussion**

Fifty-five and 69 patients with SFTS were reported to the NIID during the first and the second study periods, respectively [30]. Because SFTS is designated as a notifiable infectious disease, doctors should notify patients with SFTS within 24 hours to the NIID under the regulation of the Infectious Disease Control Law. Therefore, it can be considered that one hundred twenty-four patients reported in total include most of the patients diagnosed with SFTS in Japan. Because all the patients enrolled in this study had also been reported to the NIID, 18.5% of all the patients with SFTS reported to the NIID during the study periods were enrolled in this study and treated with favipiravir.

Favipiravir is converted to its phosphoribosylated metabolites (favipiravir-RMP and favipiravir-RTP) by host cellular kinases, and favipiravir-RTP inhibits the activity of the RNA-dependent RNA polymerase of various RNA viruses [19,31]. The CFR (17.4%) in this study was...
lower than those reported previously (31% and 27%) in Japan [11,12]. On the other hand, the ribavirin’s efficacy is insufficient and limited [13,16,32–37].

There were no significant differences between the Fatal group and the Non-fatal group in terms of basic patient and clinical characteristics (Table 1) and combination therapies except for mechanical ventilation-based respiratory support (Table 5). A difference in viral genome load was evident at the time of drug initiation (Fig 3 and Table 3). Although the number of the Fatal group and the Non-fatal group were small, the difference was statistically significant. Furthermore, the Fatal group patients received mechanical ventilation-based respiratory support more than the Non-fatal group patients (Table 5). This finding is in accordance with the previous report, in which it was shown that the higher viremia level was a strong risk factor for poor prognosis [13]. The CFRs in SFTS patients with SFTS $\geq 1 \times 10^5$ copies/mL of SFTSV genome viremia and those with SFTS $< 1 \times 10^5$ copies/mL of SFTSV genome viremia in the previous study, in which the association between SFTSV genome levels and outcome was examined in Japan, were 56% (14 of 25 SFTS patients died) and 8% (1 of 12 died), respectively [15]. The decrease in the CFR of the patients treated with favipiravir from those of the previous study in Japan might be achieved by the favipiravir treatment suggesting an efficacy of favipiravir treatment [11,12,15]. It is evident that the results in the present study should not simply be compared with those of these previous studies. This non-comparative design limited our ability to conclude whether favipiravir can reduce the incidence of fatal cases among SFTS patients. However, favipiravir treatment may offer patients with SFTS not only the therapeutic effect in reducing the mortalities, but also that in reducing morbidities. Because SFTSV replicates in the incubation period and the early phase of the disease, the efficacy of favipiravir treatment would be higher, if favipiravir treatment was initiated earlier in early phase of the disease. To have an efficacy, the drug should be initiated as early as possible.

It is written that the peak concentrations of favipiravir in healthy individuals, who were administered orally with favipiravir 1,600 mg twice a day followed by 600 mg/day twice a day for 4 days, was approximately 65 μg/mL [38]. It suggests that higher dose of favipiravir should be prescribed for patients with SFTS than that for patients with influenza virus infection. The dosage of favipiravir for patients with SFTS used in this study might be acceptable. Because pharmacokinetic data on favipiravir in patients with SFTS is limited, further study is needed. It is known that gastrointestinal tract symptoms including bloody bowel discharge and bloody vomiting [4,26,39]. Considering the high frequency of central nervous system symptoms and gastrointestinal symptoms in SFTS patients, intravenous administration of favipiravir may be preferable.

The high frequency of hepatic dysfunction as an AE and the observed delay in its improvement are informative when considering the use of favipiravir. As the frequency of liver disorders in SFTS patients is high, it is unclear whether this is merely a side effect of favipiravir.

The CFR of SFTS in Japan could be reduced by approximately 10% by the treatment with favipiravir. There has been a report describing two patients with SFTS treated with favipiravir [40]. In the report, patient #1, a 38-year-old man, and patient #2, a 48-year-old man, were administered favipiravir from day 4 and day 11 from disease onset, respectively. Both patients survived. Because the number of the patients treated with favipiravir is limited in the present study, comparative studies with a larger sample size are warranted to confirm the effects of favipiravir on clinical outcome. The present study suggests that favipiravir may be an effective drug in treatment for patients with SFTS.

Supporting information

S1 Table. Rank classification of clinical symptoms and laboratory findings. For making it available to assess the clinical course of the SFTS patients treated with favipiravir in terms of
severity and outcome, severity level of clinical symptoms and laboratory findings were classified in accordance with a pre-specified rank (S1 Table). In brief, the classifications were as follows, Rank 1, normal level; Rank 2, mild level; Rank 3, moderate level; and Rank 4, severe level. (DOCX)

**S2 Table. Clinical characteristics of patients on admission.** The signs and symptoms of body temperature, headache, Body aches and pains, vomiting, abdominal pain diarrhea, dyspnea, hemorrhagic symptoms, and disorientation of the patients enrolled in the present study on admission was evaluated. The statistical difference was evaluated on each manifestation between the Fatal and Non-fatal groups (S2 Table). The signs and symptoms evident on admission did not significantly differ between the Fatal and Non-fatal groups. (DOCX)

**Acknowledgments**

We thank Ms. Risako Yamashita, Ms. Akane Doi, and Ms. Rina Ando (Center for Clinical Research Data and Biostatistics, Ehime University Hospital) and Ms. Naoko Nagata (ALMEC Co., Ltd., Osaka, Japan) for the collection of data from each facility, and the municipal officials who supported this work in the prefectures where SFTS patients were reported. We thank all the staff, who performed the RT-PCR test in the following Prefectural and Municipal Public Health Institutes; Kagoshima Prefectural Institute for Environmental Research and Public Health (Kagoshima 892–0836, Japan), Miyazaki Prefectural Institute for Public Health and Environment (Miyazaki 889–2155, Japan), Kumamoto Prefectural Institute of Public-Health and Environmental Science (Kumamoto 869–0425, Japan), Kumamoto City Environmental Research Center (Kumamoto 862–0946, Japan), Nagasaki Municipal Public Health and Environment Laboratory (Nagasaki 852–8104, Japan), Nagasaki Prefectural Institute of Environment and Public Health (Nagasaki 856–0026, Japan), Fukuoka Institute of Health and Environmental Sciences (Fukuoka 818–0135, Fukuoka, Japan), Fukuoka City Institute of Health and Environment (Fukuoka 810–0065, Japan), Kochi Public Health and Environmental Science Research Institute (Kochi 780–0850, Japan), Ehime Prefectural Institute of Public Health and Environmental Science (Ehime 790–0003, Japan), Kagawa Prefectural Research Institute for Environmental Sciences and Public Health (Kagawa 760–0065, Japan), Tokushima Prefectural Public Health, Pharmaceutical and Environmental Sciences Center (Tokushima 770–0855, Japan), Yamaguchi Prefectural Institute of Public Health and Environment (Yamaguchi 753–0821, Japan), Hiroshima City Institute of Public Health (Hiroshima 733–8650, Japan), Hiroshima Prefectural Technology Research Institute, Public Health and Environment Center (Hiroshima 734–0007, Japan), and Mie Prefecture Health and Environment Research Institute (Mie 512–1211, Japan)

**Trial registration number:**

UMIN Clinical Trials Registry, UMIN000022398 (https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000025710) and UMIN000029020 (https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000033194).

**Author Contributions**

**Conceptualization:** Masayuki Saijo, Masaki Yasukawa.

**Data curation:** Koichiro Suemori, Atsushi Yamanaka, Daisuke Himeji, Masafumi Kawamura, Takashi Haku, Michihiro Hitaka, Chinatsu Kamikokuryo, Yasuyuki Kakihana, Taichi Azuma, Katsuto Takenaka, Toru Takahashi, Akitsugu Furumoto, Toshiyuki Ishimaru,
Masayuki Ishida, Masahiko Kaneko, Norimitsu Kadowaki, Kenichi Ikeda, Shigetoshi Sakabe, Tomohiro Taniguchi, Hiroki Ohge, Takeshi Kurosu, Tomoki Yoshikawa, Masayuki Shimojima.

Formal analysis: Koichiro Suemori, Masayuki Saijo, Masayuki Shimojima, Masaki Yasukawa.

Funding acquisition: Masayuki Saijo, Masayuki Shimojima, Masaki Yasukawa.

Investigation: Koichiro Suemori, Atsushi Yamanaka, Daisuke Himeji, Masafumi Kawamura, Takashi Haku, Michihiro Hidaka, Chinatsu Kamikokuryo, Yasuyuki Kakihama, Taichi Azuma, Katsuto Takenaka, Toru Takahashi, Akitsugu Furumoto, Toshiyuki Ishimaru, Masayuki Ishida, Masahiko Kaneko, Norimitsu Kadowaki, Kenichi Ikeda, Shigetoshi Sakabe, Tomohiro Taniguchi, Hiroki Ohge, Takeshi Kurosu, Tomoki Yoshikawa, Masayuki Shimojima.

Methodology: Masayuki Saijo, Masayuki Shimojima, Masaki Yasukawa.

Project administration: Masaki Yasukawa.

Supervision: Masayuki Saijo, Masaki Yasukawa.

Validation: Koichiro Suemori, Masayuki Saijo, Masayuki Shimojima, Masaki Yasukawa.

Writing – original draft: Koichiro Suemori.

Writing – review & editing: Masayuki Saijo, Masaki Yasukawa.

References

1. Yu XJ, Liang MF, Zhang SY, Liu Y, Li JD, Sun YL, et al. Fever with thrombocytopenia associated with a novel bunyavirus in China. N Engl J Med. 2011; 364:1523–32. https://doi.org/10.1056/NEJMoa1010095 PMID: 21410387

2. Xu B, Liu L, Huang X, Ma H, Zhang Y, Du Y, et al. Metagenomic analysis of fever, thrombocytopenia and leukopenia syndrome (FTLS) in Henan Province, China: discovery of a new bunyavirus. PLoS Pathog. 2011; 7:e1002369. https://doi.org/10.1371/journal.ppat.1002369 PMID: 22114553

3. Kim KH, Yi J, Kim G, Choi SJ, Jun KI, Kim NH, et al. Severe fever with thrombocytopenia syndrome, South Korea, 2012. Emerg Infect Dis. 2013; 19: 1892–4. https://doi.org/10.3201/eid1911.130792 PMID: 24206586

4. Takahashi T, Maeda K, Suzuki T, Ishido A, Shigeoka T, Tominaga T, et al. The first identification and retrospective study of severe fever with thrombocytopenia syndrome in Japan. J Infect Dis. 2014; 209:816–27. https://doi.org/10.1093/infdis/jit603 PMID: 24231186

5. Saijo M. Circulation of severe fever with thrombocytopenia syndrome virus (SFTSV) in nature: transmission of SFTSV between mammals and ticks. In: Saijo M, editor. Severe fever with thrombocytopenia syndrome: Singapore: Springer Nature. 2019: 151–72. https://doi.org/10.1007/978-981-13-9562-8_13

6. Kida K, Matsuoka Y, Shimoda T, Matsuoka H, Yamada H, Saito T, et al. A case of cat-to-human transmission of severe fever with thrombocytopenia syndrome virus. Jpn J Infect Dis. 2019; 72:356–8. https://doi.org/10.7883/yokenJJID.2018.526 PMID: 31366857

7. Lin TL, Ou SC, Maeda K, Shimada H, Chan JPW, Tu WC, et al. The first discovery of severe fever with thrombocytopenia syndrome virus in Taiwan. Emerg Microbes Infect. 2020; 9:148–51. https://doi.org/10.1080/22221751.2019.1710436 PMID: 31918622

8. Peng SH, Yang SL, Tang SE, Wang TC, Hsu TC, Su CL, et al. Human case of severe fever with thrombocytopenia syndrome virus infection, Taiwan, 2019. Emerg Infect Dis. 2020; 26(7):1612–4. https://doi.org/10.3201/eid2607.200104 PMID: 32598884

9. Tran XC, Yun Y, Van An L, Kim SH, Thao NTP, Man PKC, et al. Endemic severe fever with thrombocytopenia syndrome, Vietnam. Emerg Infect Dis. 2019; 25: 1029–31. https://doi.org/10.3201/eid2505.181463 PMID: 31002059

10. Shin J, Kwon D, Youn SK, Park JH. Characteristics and factors associated with death among patients hospitalized for severe fever with thrombocytopenia syndrome, South Korea. 2013 Emerg Infect Dis. 2015; 21:1704–10. https://doi.org/10.3201/eid2110.141928 PMID: 26402575
11. Kato H, Yamagishi T, Shimada T, Matsu T, Shimojima M, Saijo M, et al. Epidemiological and clinical features of severe fever with thrombocytopenia syndrome in Japan, 2013–2015. PLoS One. 2016; 11: e0165207. https://doi.org/10.1371/journal.pone.0165207 PMID: 27776187

12. Kobayashi Y, Kato H, Yamagishi T, Shimada T, Matsu T, Yoshikawa T, et al. Epidemiological study of severe fever with thrombocytopenia syndrome in Japan, 2013–2017. Emerg Infect Dis. 2020; 26 (4):692–9. https://doi.org/10.3201/eid2604.191011 PMID: 32186502

13. Li H, Lu QB, Xing B, Zhang SF, Kiu K, Du J, et al. Epidemiological and clinical features of laboratory-diagnosed severe fever with thrombocytopenia syndrome in China, 2011–17: a prospective observational study. Lancet Infect Dis. 2018; 18:1127–37. https://doi.org/10.1016/S1473-3099(18)30293-7 PMID: 30054190

14. Park SW, Ryoo J, Choi WY, Han MG, Lee WJ. Epidemiological and clinical features of severe fever with thrombocytopenia syndrome during an outbreak in South Korea, 2013–2015. Am J Trop Med Hyg. 2016; 95:1358–61. https://doi.org/10.4269/ajtmh.16-0251 PMID: 27928084

15. Yoshikawa T, Fukushima T, Tani H, Fukuma A, Taniguchi S, Toda S, et al. Sensitive and specific PCR systems for detection of both Chinese and Japanese severe fever with thrombocytopenia syndrome virus strains and prediction of patient survival based on viral load. J Clin Microbiol. 2015; 52:3325–33. https://doi.org/10.1128/JCM.00742-14 PMID: 24989600

16. Chen Y, Jia B, Liu Y, Huang R, Chen J, Wu C. Risk factors associated with fatality of severe fever with thrombocytopenia syndrome: a meta-analysis. Oncotarget. 2017; 8:99119–29. https://doi.org/10.18632/oncotarget.19163 PMID: 29179504

17. Nakamura S, Azuma M, Maruhashi T, Sogabe K, Sumitani R, Uemura M, et al. Steroid pulse therapy in patients with encephalopathy associated with severe fever with thrombocytopenia syndrome. J Infect Chemother. 2018; 24:389–92. https://doi.org/10.1016/j.jiac.2017.11.004 PMID: 29428565

18. Oh WS, Yoo JR, Kwon KT, Kim HI, Lee SJ, Jun JB, et al. Effect of early plasma exchange on survival in patients with severe fever with thrombocytopenia syndrome: a multicenter study. Yonsei Med J. 2017; 58: 867–71. https://doi.org/10.3349/ymj.2017.58.4.867 PMID: 28541003

19. Furuta Y, Takahashi K, Fukuda Y, Kuno M, Kamiyama T, Kozaki K, et al. In vitro and in vivo activities of anti-influenza virus compound T-705. Antimicrob Agents Chemother. 2002; 46(4):977–81. https://doi.org/10.1128/AAC.46.4.977-981.2002 PMID: 11897578

20. Tani H, Fukushima A, Fukushima T, Taniguchi S, Yoshikawa T, IWata-Yoshikawa N, et al. Efficacy of T-705 favipiravir in the treatment of infections with lethal severe fever with thrombocytopenia syndrome virus. mSphere. 2016; 1:e00061–15. https://doi.org/10.1128/mSphere.00061-15 PMID: 27303697

21. Tani H, Komeno T, Fukushima A, Fukushima T, Taniguchi S, Shimojima S, et al. Therapeutic effects of favipiravir against severe fever with thrombocytopenia syndrome virus infection in lethal mouse model: dose-efficacy studies upon oral administration. PLoS One. 2018; 13:e0206416. https://doi.org/10.1371/journal.pone.0206416 PMID: 30365543

22. Gowen BB, Westover JB, Miao J, Van Wettere AJ, Rigas JD, Hickerson BT, et al. Modeling severe fever with thrombocytopenia syndrome virus infection in golden Syrian hamsters: Importance of STAT2 in preventing disease and effective treatment with favipiravir. J Virol. 2017; 91: e01942–16. https://doi.org/10.1128/JVI.01942-16 PMID: 27881648

23. Cyranoski D. East Asia braces for surge in deadly tick-borne virus. Nature. 2018; 556:282–3. https://doi.org/10.1038/d41586-018-04486-6 PMID: 29666487

24. Bruix J, Sherman M. American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011; 53:1020 –2. https://doi.org/10.1002/hep.24195 PMID: 21374666

25. Ministry of Health, Labour, and Welfare of Japan. Criteria for seriousness classification of adverse drug reactions (PAB/SD Notification No. 80) issued by the Director of Safety Division, Pharmaceutical Affairs Bureau on June 29, 1992. Available from: https://www.mhlw.go.jp/content/1121000/000529049.pdf., (accessed on 13rd July, 2020, in Japanese).

26. Saijo M. Pathophysiology of severe fever with thrombocytopenia syndrome and development of specific antiviral therapy. J Infect Chemother. 2018; 24:773–81. https://doi.org/10.1016/j.jiac.2018.07.009 PMID: 30098914

27. Jung JY, Ahn K, Kim JY, Choi JY, Kim HY, Uh Y, et al. Higher fatality for severe fever with thrombocytopenia syndrome complicated by hemophagocytic lymphohistiocytosis. Yonsei Med J. 2019; 60:592–6. https://doi.org/10.3349/ymj.2019.60.6.592 PMID: 31124344

28. Kwon JS, Kim MC, Kim JY, Jeon NY, Ryu BH, Hong J, et al. Kinetics of viral load and cytokines in severe fever with thrombocytopenia syndrome. J Clin Virol. 2018; 101:57–62. https://doi.org/10.1016/j.jcv.2018.01.017 PMID: 29427908
29. Sun Y, Jin C, Zhan F, Wang X, Liang M, Zhang Q, et al. Host cytokine storm is associated with disease severity of severe fever with thrombocytopoenia syndrome. J Infect Dis. 2012; 206:1085–94. https://doi.org/10.1093/infdis/ijs452 PMID: 22904342

30. National Institute of Infectious Diseases. Summary of severe fever with thrombocytopoenia syndrome cases reported to the National Epidemiological Surveillance of Infectious Diseases. Available from: https://www.nih.go.jp/niiid/ja/sfts/sfts-idwrs/7415-sfts-nesid.html, (accessed on 14th November, 2020, in Japanese).

31. Furuta Y, Gowen BB, Takahashi K, Shiraki K, Smee DF, Barnard DL. Favipiravir (T-705), a novel viral RNA polymerase inhibitor. Antivir Res. 2013; 100:446–54. https://doi.org/10.1016/j.antiviral.2013.09.015 PMID: 24084488

32. Ding F, Zhang W, Wang L, Hu W, Magalhaes RJS, Sun H, et al. Epidemiologic features of severe fever with thrombocytopoenia syndrome in China, 2011–2012. Clin Infect Dis. 2013; 56:1682–3. https://doi.org/10.1093/cid/cit100 PMID: 23429379

33. Zhang YZ, Zhou DJ, Xiong Y, Chen XP, He YW, Sun Q, et al. Hemorrhagic fever caused by a novel tick-borne Bunyavirus in Huaiyangshan, China. Zhonghua Liu Xing Bing Xue Za Zhi. 2011; 32: 209–20. (in Chinese) PMID: 21457654.

34. Gai ZT, Zhang Y, Liang MF, Jin C, Zhang S, Zhu CB, et al. Clinical progress and risk factors for death in severe fever with thrombocytopoenia syndrome patients. J Infect Dis. 2012; 206:1095–102. https://doi.org/10.1093/infdis/ijs472 PMID: 22850122

35. Oh WS, Heo ST, Kim SH, Choi WJ, Han MG, Kim JY. Plasma exchange and ribavirin for rapidly progressive severe fever with thrombocytopoenia syndrome. Int J Infect Dis. 2014; 18:84–6. https://doi.org/10.1016/j.ijid.2013.08.011 PMID: 24161209

36. Park I, Kim HI, Kwon KT. Two treatment cases of severe fever and thrombocytopoenia syndrome with oral ribavirin and plasma exchange. Infect Chemother. 2017; 49:72–7. https://doi.org/10.3947/ic.2017.49.1.72 PMID: 28271646

37. Liu W, Lu QB, Cui N, Li H, Wang LY, Liu K, et al. Case-fatality ratio and effectiveness of ribavirin therapy among hospitalized patients in China who had severe fever with ribavirin syndrome. Clin Infect Dis. 2013; 57:1292–9. https://doi.org/10.1093/cid/cit530 PMID: 23965284

38. Fujifilm Toyama Chemical Co., Ltd. Package insert for favipiravir tablet for the usage for patients with influenza virus infection. Available from: https://www.pmda.go.jp/PmdaSearch/iyakuDetail/ResultDataSetPDF/400022_625004XF1022_2_02 (accessed on 16th November, 2020, in Japanese).

39. Kaneyuki S, Yoshikawa T, Tani H, Fukushima S, Taniguchi S, Fukuma A, et al. Ulcerative lesions with hemorrhage in a patient with severe fever with thrombocytopoenia syndrome observed via upper gastrointestinal endoscopy. Jpn J Infect Dis. 2016; 69:525–7. https://doi.org/10.7883/yoken.JJID.2015.404 PMID: 26743149

40. Song R, Chen Z, Li W. Severe fever with thrombocytopoenia syndrome (SFTS) treated with a novel antiviral medication, favipiravir (T-705). Infection. 2020; 48:295–8. https://doi.org/10.1007/s15010-019-01364-9 PMID: 31873977